Since we last discussed Ocugen about 6 weeks ago, it’s up around 36% (from .55 to .75).May have to buy some as well. This one looks like a winner.....if they get the needed FDA approvals.
EDIT: Started reading about OCU400, looks like a competitor to Luxturna from Spark/Roche. That's one of the first gene therapies ever approved, but has limitations that OCU400 looks to mitigate. Very interesting. Much more to read.
Current corporate deck:
On Wednesday, 2/21, they will be part of a panel on gene therapy for RP, and they are bringing to the panel one of their patients who has been treated with OCU400 for 12 months.
Bringing a patient who is a member of their Phase2 trial has investors excited, at the likelihood that the patient will attest to the efficacy of OCU400 gene therapy to treat blindness caused by RP.
That presentation on Wednesday could be the catalyst to increase the share price upward towards 1.00, which will allow them to remain compliant with NASDAQ without issuing a reverse split.
This is not advice, just passing on the info.